Procedures: Tumor and adjacent liver were profiled by liquid chromatography mass spectrometry, quantifying phosphatidylcholine species by mass-to-charge ratio. For clinicalradiopathologic correlation, HCC profiles were reduced to two orthogonal principal component factors (PCF1 and PCF2) accounting for 80 % of total profile variation. Results: Tissues from 31 HCC patients and 4 intrahepatic cholangiocarcinoma (ICC) patients were analyzed, revealing significantly higher levels of phosphocholine, CDP-choline, and highly saturated phosphatidylcholine species in HCC tumors relative to adjacent liver and ICC tumors. Significant loading values for PCF1 corresponded to phosphatidylcholines containing poly-unsaturated fatty acids while PCF2 corresponded only to highly saturated phosphatidylcholines. Only PCF2 correlated significantly with HCC tumor-to-liver [ 
Introduction
Liver cancer is the third leading cause of cancer death worldwide and is expected to surpass breast, prostate, and colorectal cancer to become the third leading cause of cancer death in the USA by 2030 [1] . Surgery is the most effective treatment for early-stage liver cancer, but accurate tumor characterization and staging is necessary to select appropriate surgical candidates. To this end, imaging techniques such as ultrasound, X-ray computed tomography (CT), and magnetic resonance imaging have assumed important roles in evaluating possible liver cancer [2] . There is also growing interest in molecular imaging of the liver, since techniques such as positron emission tomography (PET) can potentially detect molecular biological changes antecedent to tumor growth and invasion. However, imaging with 2-deoxy-2-[ 18 F ]fluoro-D-glucose ([ 18 F ]FDG), the predominant oncologic PET tracer, may not be well suited for liver cancer, since its diagnostic sensitivity for hepatocellular carcinoma (HCC), the most common primary liver cancer, has been estimated in the range of 50-60 % [3] .
Liver tissues have an enormous proliferative capacity due in part to an ability to synthesize large quantities of phosphatidylcholine (PtC), the most abundant membrane phospholipid [4] . Some of this capacity is likely preserved in liver cancer to support tumor cell proliferation [5] . Hepatocytes also utilize PtC to produce lipid particles and bile solvents, and liver dysfunction is known to involve significant changes in phospholipid metabolism [4, 6] . Thus, phospholipids such as PtC might be able to serve as chemical biomarkers for a variety of liver diseases including liver cancer [6] .
PtC is composed of two fatty acids and one phosphocholine moiety bound to a glycerol backbone. Molecular species of PtC vary by the length and degree of saturation of their fatty acyl components, resulting in broad functional variations [7, 8] . Higher levels of PtC species containing saturated fatty acyl groups have been found in many cancers [9] and are associated with biological aggressiveness in breast and thyroid cancer [10, 11] . There are several potential mechanisms to explain how phospholipids may influence tumor biology. First, fatty acyl group saturation may directly influence phospholipid membrane fluidity, potentially protecting tumors from exogenous insults while facilitating malignant invasion [11, 12] . Second, phospholipid composition can also affect membrane protein distribution and thus modulate intracellular transport and cell signaling [8] . And third, saturated fatty acids are less susceptible to peroxidation, potentially rendering tumors more resilient to oxidative stress [12] . Thus, a non-invasive means to characterize tumor phospholipids may have diagnostic, prognostic, and possibly therapeutic predictive value in cancer.
Results from a recent single-institution trial indicate that P E T / C T u s i n g [ 1 8 F ] f l u o r o m e t h y l -d i m e t h y l -2 -hydroxyethylammonium ([ 18 F] fluorocholine) is more sensitive than [ 18 F ]FDG PET/CT for detecting HCC [13] . As a synthetic tracer, [ 18 F] fluorocholine behaves as a substrate for choline kinase (CK) [14] , enabling PET to image the initial steps of choline metabolism leading to PtC synthesis. While variability in tumor [ 18 F] fluorocholine uptake has been associated to some extent with histopathologic features of liver tumors [13, 15] , the association between tumor phospholipid composition and [ 18 F ]fluorocholine uptake has not yet been extensively investigated. In the present study, a targeted metabolomics approach was used to profile the phospholipids of resected tumor specimens imaged preoperatively with [ 18 F] fluorocholine PET/CT to investigate the relationship between [
18 F]fluorocholine uptake and phospholipid composition in liver cancer.
Methods

Patients
Patients undergoing partial hepatectomy for liver cancer were prospectively enrolled to this single-institution study. All patients gave written informed consent under an institutional review board-approved clinical research protocol. Deidentified data obtained from medical records included cancer-specific variables such as tumor size and serum alpha-fetoprotein level. [16] . All radiopharmaceuticals passed standard assays for purity, radionuclidic identity, and non-pyrogenicity before injection, with radiochemical purity exceeding 99 %.
PET/CT images were obtained using a Philips Gemini TF-64 PET/CT (Philips Healthcare, Andover, MA). For attenuation correction, a CT transmission scan of the abdomen was performed in the supine position. The 64-channel helical CT scanning parameters were as follows: 120 kV, 50 mA/slice, rotation time 0.75 s, slice thickness/ interval 5.0 mm. No iodinated intravenous contrast was used for CT. Afterward, dynamic PET was performed over 30 min in 31 dynamic-imaging frames upon injection of 2.2 to 3.0 MBq/kg of [ 18 [17] . Because of the rapid blood clearance of [ 18 F] fluorocholine, an image-derived input function was used in lieu of direct arterial blood sampling by placing an 8-mm diameter ROI over the descending aorta and fitting the ROI time-activity curve (TAC) with a three-exponential decay function [18, 19] . Tumor and liver TAC data were generated using the ROIs defined for static measurements. The following rate constants were analyzed: k1 and k2, representing transport into and out of cells, respectively, and k3 and k4, representing intracellular phosphorylation and dephosphorylation of [ 18 F] fluorocholine, respectively.
Tissue Sampling
Tissue samples were collected immediately after surgical procurement of the tumor-bearing hepatic segment, avoiding areas of necrosis and hemorrhage. A section from each sample was placed in liquid nitrogen and transported in a cryogenic dewar to a central biorepository for storage at −196°C. There were no thaw-freeze cycles prior to chemical extraction. Sections from each sample were also placed in formalin for histopathology and liver tissue grading.
Chemical Extraction
Tissue extracts were partitioned between an aqueous and chloroform phase using previously published methods [20, 21] . Briefly, tissue was freeze-dried and homogenized with a mortar and pestle, combined with isotopically labeled internal standards (~10 μl of a 10,000 ng/ml solution), and triple extracted with 400 μl MeOH/CHCl 3 (2:1) containing 1 μg/ml butylated hydroxytoluene. The extracts combined with the solids were stored at −20°C overnight. After vortexing and centrifugation, the liquid phase was separated, and the residue was vortexed with 500 μl MeOH/CHCl 3 / H 2 O (2:1:0.8) and centrifuged. The supernatant was combined with the liquid phase for analysis of lipophilic PtC metabolites.
Phospholipid Profiling
Tissues were analyzed using liquid chromatography-mass spectrometry (LC-MS) by injecting 10 μl of tissue extract via a PAL autosampler onto a Luna HILIC column (150 mm × 3 mm; 3 μm; Phenomenex) containing a precolumn filter (0.2 μm; Thermo). A linear gradient elution was performed using MeCN (solvent A) and 40 mM aqueous ammonium acetate at pH 3.5 (solvent B) at 0. [21] . Classes of phospholipids were quantified in ng/mg of tissue using authentic standards. Tissue levels of phosphocholine, glycerophosphocholine, and CDP-choline were analyzed based on published methods [22] .
Statistics and Informatics
Paired results were assessed by Wilcoxon signed-rank test. Correlations were assessed by the Spearman coefficient. A principal component analysis (PCA) was conducted to reduce the dimensionality of raw LC-MS data and facilitate clinical and radiopathologic correspondence. Principal components with eigenvalues greater than 1.5 were considered significant. Following standard varimax rotation, component scores derived from the rotated factor loading coefficients were evaluated for correlations with PET and clinical data.
To obtain chemical data associated with each principal component factor (PCF), the Human Metabolome Database (http://www.hmdb.ca) was queried over the range of massto-charge (m/z) ratios (732.5537 to 836.6099) corresponding to the PtC class of phospholipids [21] . Queries were conducted in ESI-positive mode and adduct type M + H with a molecular weight tolerance of ±5 ppm. All statistical and principal component analyses were performed using Table 1 . One patient underwent transarterial chemotherapy embolization in preparation for liver transplantation, with PET/CT revealing no focal increased liver uptake and the explanted liver revealing no viable tumor. Excluding this case, there were 37 HCC and 4 intrahepatic c h o l a n g i o c a r c i n o m a ( I C C ) t u m o r s c o n f i r m e d histopathologically. 
PET/CT Results
Histopathologic Analysis
Only a single tumor was identified in each partial hepatectomy specimen. Areas of necrosis were noted on histology in 8 HCC specimens (5 moderately differentiated tumors and 3 undifferentiated tumors). Vascular invasion was identified in 8 HCC specimens (3 moderately differentiated tumors, 3 poorly differentiated tumors, and 2 undifferentiated tumors). There was not enough tumor tissue available for tissue profiling in 6 patients with HCC: 4 with small tumors (largest diameters from 1.3 to 1.8 cm) and 2 with necrotic tumors. Therefore, tumor and adjacent liver tissues from only 31 HCC cases could be profiled, although 5 of the 6 tumors not profiled were detectable on [ 
Phospholipids Analysis
PtC was found to be the most abundant phospholipid in the HCC tumor samples, accounting for 70 % of total phospholipids, followed by phosphatidylethanolamine (15 %), phosphatidylinositol (14 %), lysophosphatidylcholine (G1 %), and sphingomyelins (G1 % Table 3 . Several PET parameters were significantly correlated with tumor levels of phosphocholine and total PtC, as shown in Table 4 . 
Principal Component Analysis
Scree and variance plots for PCA of the 31 HCC samples are shown in Fig. 3 . The first two PCA eigenvectors accounted for approximately 80 % of total profile variation ( Table 5 ). The loading value results from a rotated PC factor (PCF) analysis of the HCC profile data are shown in (Fig. 4) . Referring to the Human Metabolome Database, these ranges of m/z all correspond to PtC species containing long polyunsaturated fatty acyl (PUFA) groups (Supplementary Table 1 ). In contrast, the significant loading values of principal component factor 2 (PCF2) corresponded to species with m/z in the range of 732.5537, 734.5667, and 760.5814 (Fig. 4) . These ranges were ascribed in the Human Metabolome Database only to PtC species containing highly saturated fatty acyl (HSFA) groups (Supplementary Table 2 ) that are products of stearoyl-CoA desaturase-1 (SCD1) and other human-occurring fatty acid CoA desaturases [23] . In contrast, the m/z values associated with the significant loading values for PCF1 indicated more complex mixtures of fatty acids that include longer highly unsaturated fatty acids, as well as linoleic acid (C18:2) and alpha-linolenic acid (C18:3), which cannot be synthesized de novo by humans (i.e., derived from essential fatty acids). PtC phosphatidylcholine, CDP-choline cytidine diphosphate choline, m/z mass-to-charge ratio 
Discussion
The CDP-choline pathway that produces PtC from choline is a constitutive metabolic pathway in hepatocytes, supporting not only membrane production but also the synthesis of lipid particles and bile solvents [24] . In liver cancer as well as other cancers, there appears to be upregulation of this pathway in support of tumor cell proliferation [5, 25] . Molecular imaging of the initial steps of this pathway is enabled by [ 18 F] fluorocholine PET/CT [14] , with singleinstitution trials showing it to have high diagnostic sensitivity for several malignancies that can elude detection by conventional FDG PET/CT, such as prostate cancer and HCC [13, 26] . The present study correlates choline metabolism (depicted by [ 18 F] fluorocholine PET/CT) with lipid composition in liver cancer, revealing a preponderance of HSFA PtC species in the tumors demonstrating increased [ 18 F]fluorocholine metabolism. These results indicate that upregulated choline metabolism and de novo lipogenesis are jointly involved in satisfying the demand for PtC in malignancy.
In the context of metabolic reprogramming, it would not be surprising for choline phospholipid metabolism to join with other metabolic pathways such as fatty acid synthesis in support of tumor cell survival and proliferation [27] . Increased rates of de novo fatty acid synthesis have been observed in many cancers [28] , and preclinical experiments using radiolabeled acetate have shown that a significant proportion of de novo fatty acids are incorporated by PtC in HCC [29] . Indeed, [
11 C]-acetate has been proposed as a PET tracer for detecting HCC on the basis of imaging de novo fatty acid synthesis, with clinical studies supporting its potential diagnostic efficacy [30] . The consumption of de novo fatty acids for cell membrane synthesis may help explain the significant overlap between cancers that can be detected by choline PET and by acetate PET. However, recently, it was shown that some HCC tumors show low [ 11 C]acetate uptake despite increases in de novo lipogenesis and FASN expression [31] . While the mechanism underlying this paradoxical observation is not yet fully clarified, it is known that acetate participates in other metabolic pathways besides lipogenesis, including oxidative metabolism, histone acetylation, and cholesterol synthesis [32] . Therefore, multiple pathways may be regulating acetate metabolism, thus reducing the fidelity of [ The coordination between lipogenesis and phospholipid synthesis in HCC might involve sterol regulatory elementbinding protein 1 (SREBP-1), a nuclear transcription factor that controls multiple elements of lipid metabolism [33] . SREBP-1 has also been shown to regulate elements of the CDP-choline pathway [34] . SREBP-1 can be activated by PI3K/Akt signaling, recruiting lipogenesis to meet the metabolic demands of malignant tumors [33] . Since S R E B P -1 i s p o t e n t i a l l y a t h e r a p e u t i c t a r g e t , [ 18 F] fluorocholine PET/CT may be worth evaluating as an imaging biomarker for measuring the phospholipid effects of SREBP-1 antagonists, or other lipid pathway inhibitors, in tumors.
Applying diagnostic criteria developed in a previous clinical imaging trial [13] , we estimated the sensitivity of [ The present study has several limitations. Most notably, it included only patients with resectable tumors and consequently may not reflect the full clinical spectrum of liver cancer, including aggressive cancers that are more likely to present at late stage. Furthermore, there was not enough sample tissue to conduct phospholipid metabolite profiling in six cases. Given a small cohort, this might raise concern for selection bias; however, the pathologic and imaging characteristics of profiled and unprofiled tumors were comparable. In addition, since patients with benign liver lesions are less likely to undergo surgery, the diagnostic specificity of [ 18 F] fluorocholine PET/CT could not be realistically estimated. Previous studies have reported that non-cancerous conditions such as focal nodular hyperplasia and cholangitis can manifest with increased [
18 F]fluorocholine uptake [13] . Larger studies involving a broader series of patients will be needed to fully characterize the diagnostic performance of [ 18 F ]fluorocholine PET/CT in patients presenting with liver masses.
Although the prognostic significance of increased [ 18 F] fluorocholine uptake in liver cancer is not yet certain, we recently found by immunohistochemical profiling of a liver cancer tissue microarray that overexpression of choline kinase was associated with diminished overall survival in HCC [36] . An enzyme responsible for producing the monounsaturated fatty acids comprising PCF2 (th e com pon en t a sso cia t ed with tu mor [ 18 F] fluorocholine uptake), SCD-1, has also been shown to promote tumor cell survival and chemotherapy resistance in HCC [37] . Thus, it may be worthwhile to conduct further research on the prognostic or predictive value of [ 18 F] fluorocholine PET/CT in HCC.
Conclusion
In this study, the phospholipid metabolomes of surgically resected liver cancers were profiled in a targeted manner, revealing that levels of highly saturated PtC species increased in HCC in correlation with [ 18 F]fluorocholine uptake on PET/CT. These findings imply that the CDPcholine pathway may have dependency on de novo fatty acid metabolism in supplying PtC in HCC. Findings from the present study may support the use of [ 18 F] fluorocholine PET/CT to identify tumors with lipogenic phenotypes, with potential applications as a prognostic or therapeutic biomarker in HCC.
